Adding lenvatinib to standard treatment for methylated glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial compares the usual treatment (radiation plus a chemotherapy drug called temozolomide) with the same treatment plus an extra drug called lenvatinib. The goal is to see if adding lenvatinib helps people with a certain type of glioblastoma live longer or keep the tumor from growing back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of brain cancer called glioblastoma that was recently diagnosed and has a positive MGMT methylation test (a lab result that may help certain treatments work better).
- You must be between 18 and 75 years old, and your general health (KPS score) must be 70 or above, meaning you can do most daily activities on your own.
- You must not have had radiation or chemotherapy for this brain tumor before.
- Your liver, kidney, and blood levels need to be within safe ranges as checked by blood tests.
- If you take steroids to control brain swelling, the dose must be stable or reduced for at least two weeks before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
This trial tests whether adding the drug ruxolitinib to standard radiation and chemotherapy (temozolomide) helps people with a newly diagnosed brain tumor called glioblastoma. It aims to see if the combination keeps the tumor from growing longer than the standard treatment alone.
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
This trial tests adding lomustine chemotherapy to standard treatment for people with a specific type of glioblastoma that has a methylated MGMT gene. It aims to see if this combination helps control the tumor better and improves survival.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.